MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Acquired by Barclays PLC

Barclays PLC grew its position in MeiraGTx Holdings plc (NASDAQ:MGTX - Free Report) by 107.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 147,827 shares of the company's stock after buying an additional 76,437 shares during the quarter. Barclays PLC owned 0.19% of MeiraGTx worth $618,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets lifted its stake in MeiraGTx by 142.5% in the third quarter. BNP Paribas Financial Markets now owns 9,319 shares of the company's stock worth $39,000 after acquiring an additional 5,476 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of MeiraGTx by 97.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,886 shares of the company's stock valued at $62,000 after purchasing an additional 7,330 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of MeiraGTx by 19.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,763 shares of the company's stock worth $75,000 after purchasing an additional 2,839 shares during the period. SG Americas Securities LLC bought a new position in shares of MeiraGTx during the third quarter valued at approximately $82,000. Finally, Hsbc Holdings PLC increased its holdings in MeiraGTx by 100.9% during the second quarter. Hsbc Holdings PLC now owns 23,954 shares of the company's stock valued at $102,000 after buying an additional 12,029 shares during the period. Institutional investors own 67.48% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MGTX. Royal Bank of Canada upped their target price on MeiraGTx from $9.00 to $11.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. Chardan Capital reissued a "buy" rating and issued a $36.00 price target on shares of MeiraGTx in a research report on Monday, November 18th.

MeiraGTx Stock Up 5.6 %

Shares of MeiraGTx stock traded up $0.33 on Friday, reaching $6.26. The stock had a trading volume of 445,636 shares, compared to its average volume of 320,712. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.86. The stock has a market capitalization of $489.22 million, a P/E ratio of -5.17, a P/E/G ratio of 0.34 and a beta of 1.26. The company has a 50 day moving average price of $6.25 and a 200 day moving average price of $5.18. MeiraGTx Holdings plc has a 1 year low of $3.85 and a 1 year high of $7.37.

Insider Buying and Selling at MeiraGTx

In other MeiraGTx news, CEO Alexandria Forbes sold 35,839 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total value of $231,878.33. Following the completion of the sale, the chief executive officer now directly owns 1,395,102 shares in the company, valued at approximately $9,026,309.94. This trade represents a 2.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.40% of the stock is owned by insiders.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.